MX2009010179A - Formulaciones estables de anticuerpo. - Google Patents

Formulaciones estables de anticuerpo.

Info

Publication number
MX2009010179A
MX2009010179A MX2009010179A MX2009010179A MX2009010179A MX 2009010179 A MX2009010179 A MX 2009010179A MX 2009010179 A MX2009010179 A MX 2009010179A MX 2009010179 A MX2009010179 A MX 2009010179A MX 2009010179 A MX2009010179 A MX 2009010179A
Authority
MX
Mexico
Prior art keywords
formulations
provides
antibody formulations
insulin
stabilization
Prior art date
Application number
MX2009010179A
Other languages
English (en)
Inventor
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MX2009010179A publication Critical patent/MX2009010179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Abstract

La presente invención se refiere a formulaciones y métodos para la estabilización de anticuerpos. En una modalidad, la invención proporciona la formulación de solución estable de un anticuerpo IgG1 que se enlaza específicamente al receptor del factor-I similar a la insulina. En otra modalidad, la invención proporciona métodos para estabilización de anticuerpo IgG1 que se enlazan específicamente al receptor del factor-I de crecimiento similar a la insulina que comprende, liofilizar una formulación acuosa del anticuerpo. Las formulaciones pueden ser liofilizadas para estabilizar los anticuerpos durante el procesamiento y almacenaje, y después las formulaciones pueden ser reconstituidas para administración farmacéutica.
MX2009010179A 2007-03-22 2008-03-20 Formulaciones estables de anticuerpo. MX2009010179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91974407P 2007-03-22 2007-03-22
PCT/US2008/057718 WO2008116103A2 (en) 2007-03-22 2008-03-20 Stable antibody formulations

Publications (1)

Publication Number Publication Date
MX2009010179A true MX2009010179A (es) 2010-03-15

Family

ID=39766776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010179A MX2009010179A (es) 2007-03-22 2008-03-20 Formulaciones estables de anticuerpo.

Country Status (18)

Country Link
US (1) US20100260766A1 (es)
EP (1) EP2136839A4 (es)
JP (1) JP2010522208A (es)
KR (1) KR20090113340A (es)
CN (1) CN101668540A (es)
AU (1) AU2008228823A1 (es)
BR (1) BRPI0809112A2 (es)
CA (1) CA2681743A1 (es)
CR (1) CR11005A (es)
DO (1) DOP2009000222A (es)
EA (1) EA200970880A1 (es)
EC (1) ECSP099642A (es)
IL (1) IL200321A0 (es)
MX (1) MX2009010179A (es)
TN (1) TN2009000382A1 (es)
UA (1) UA96473C2 (es)
WO (1) WO2008116103A2 (es)
ZA (1) ZA200905636B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200838559A (en) * 2006-11-29 2008-10-01 Imclone Systems Inc Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
MX345226B (es) * 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
EP2358392B1 (en) * 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
DK2616090T3 (da) * 2010-09-17 2023-09-18 Takeda Pharmaceuticals Co Stabilisering af immunoglobuliner gennem vandig formulering med histidin ved svag syre til neutral ph
ES2733712T3 (es) 2010-11-05 2019-12-02 Novartis Ag Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
KR102091294B1 (ko) * 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
SI2771031T1 (en) 2011-10-28 2018-08-31 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
BR112015013223A2 (pt) 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SI3370770T1 (sl) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2907826T3 (es) * 2001-06-26 2022-04-26 Amgen Inc Anticuerpos para OPGL
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DK1475101T3 (da) * 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
AU2004212344B2 (en) * 2003-02-13 2009-05-07 Pfizer Products Inc. Uses of anti-insulin-like growth factor I receptor antibodies
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
RS20060099A (en) * 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
CA2647111A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation

Also Published As

Publication number Publication date
ECSP099642A (es) 2009-11-30
CN101668540A (zh) 2010-03-10
EA200970880A1 (ru) 2010-02-26
WO2008116103A3 (en) 2009-01-08
WO2008116103A2 (en) 2008-09-25
CR11005A (es) 2010-08-05
IL200321A0 (en) 2010-04-29
BRPI0809112A2 (pt) 2014-08-26
CA2681743A1 (en) 2008-09-25
DOP2009000222A (es) 2009-12-15
ZA200905636B (en) 2010-10-27
KR20090113340A (ko) 2009-10-29
UA96473C2 (ru) 2011-11-10
EP2136839A2 (en) 2009-12-30
EP2136839A4 (en) 2010-04-07
JP2010522208A (ja) 2010-07-01
AU2008228823A1 (en) 2008-09-25
TN2009000382A1 (en) 2010-12-31
US20100260766A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
TN2009000382A1 (en) Stable antibody formulations
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
WO2012076670A3 (en) Antibody formulation
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
WO2010100200A3 (en) Lyophilised antibody formulation
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JO3417B1 (ar) الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2007095337A3 (en) Antibody formulation
PH12014501628A1 (en) Stabilized formulations containing anti-ang2 antibodies
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
MX2019008084A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
MX360432B (es) Formulaciones farmaceuticas muy concentradas.
MX2012006831A (es) Formacion de anticuerpos.
CA2872275C (en) Stabilized formulations containing anti-dll4 antibodies
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
AU2016204324A1 (en) Antibody formulation

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal